Downregulation of hepatic lipopolysaccharide binding protein improves lipogenesis-induced liver lipid accumulation.


Por: Latorre J, Díaz-Trelles R, Comas F, Gavaldà-Navarro A, Milbank E, Dragano N, Morón S, Mukthavaram R, Ortega F, Castells-Nobau A, Oliveras-Cañellas N, Ricart W, Karmali PP, Tachikawa K, Chivukula P, Villarroya-Gombau F, López M, Giralt M, Fernández-Real JM and Moreno-Navarrete JM

Publicada: 13 sep 2022 Ahead of Print: 5 ago 2022
Resumen:
Circulating lipopolysaccharide-binding protein (LBP) is increased in individuals with liver steatosis. We aimed to evaluate the possible impact of liver LBP downregulation using lipid nanoparticle-containing chemically modified LBP small interfering RNA (siRNA) (LNP-Lbp UNA-siRNA) on the development of fatty liver. Weekly LNP-Lbp UNA-siRNA was administered to mice fed a standard chow diet, a high-fat and high-sucrose diet, and a methionine- and choline-deficient diet (MCD). In mice fed a high-fat and high-sucrose diet, which displayed induced liver lipogenesis, LBP downregulation led to reduced liver lipid accumulation, lipogenesis (mainly stearoyl-coenzyme A desaturase 1 [Scd1]) and lipid peroxidation-associated oxidative stress markers. LNP-Lbp UNA-siRNA also resulted in significantly decreased blood glucose levels during an insulin tolerance test. In mice fed a standard chow diet or an MCD, in which liver lipogenesis was not induced or was inhibited (especially Scd1 mRNA), liver LBP downregulation did not impact on liver steatosis. The link between hepatocyte LBP and lipogenesis was further confirmed in palmitate-treated Hepa1-6 cells, in primary human hepatocytes, and in subjects with morbid obesity. Altogether, these data indicate that siRNA against liver Lbp mRNA constitutes a potential target therapy for obesity-associated fatty liver through the modulation of hepatic Scd1.

Filiaciones:
Latorre J:
 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), 17007 Girona, Spain

 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

Díaz-Trelles R:
 Arcturus Therapeutics, San Diego, CA 92121, USA

Comas F:
 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), 17007 Girona, Spain

 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

Gavaldà-Navarro A:
 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

 Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine (IBUB), University of Barcelona, CIBEROBN (CB06/03/025), 08028 Barcelona, Catalonia, Spain

Milbank E:
 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

 NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain

Dragano N:
 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

 NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain

Morón S:
 Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine (IBUB), University of Barcelona, CIBEROBN (CB06/03/025), 08028 Barcelona, Catalonia, Spain

Mukthavaram R:
 Arcturus Therapeutics, San Diego, CA 92121, USA

Ortega F:
 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), 17007 Girona, Spain

 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

Castells-Nobau A:
 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), 17007 Girona, Spain

 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

Oliveras-Cañellas N:
 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), 17007 Girona, Spain

 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

Ricart W:
 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), 17007 Girona, Spain

 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

Karmali PP:
 Arcturus Therapeutics, San Diego, CA 92121, USA

Tachikawa K:
 Arcturus Therapeutics, San Diego, CA 92121, USA

Chivukula P:
 Arcturus Therapeutics, San Diego, CA 92121, USA

Villarroya-Gombau F:
 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

 Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine (IBUB), University of Barcelona, CIBEROBN (CB06/03/025), 08028 Barcelona, Catalonia, Spain

López M:
 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

 NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain

Giralt M:
 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

 Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine (IBUB), University of Barcelona, CIBEROBN (CB06/03/025), 08028 Barcelona, Catalonia, Spain

Fernández-Real JM:
 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), 17007 Girona, Spain

 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain

 Department of Medicine, University of Girona, 17003 Girona, Spain

Moreno-Navarrete JM:
 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), 17007 Girona, Spain

 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 28029, Madrid, Spain
ISSN: 21622531
Editorial
CELL PRESS, 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139, Estados Unidos America
Tipo de documento: Article
Volumen: 29 Número:
Páginas: 599-613
WOS Id: 000860720100007
ID de PubMed: 36090751
imagen Open Access

MÉTRICAS